Nocardia, a branching, filamentous bacteria, is widely distributed in the environment and can cause human infection in immune-compromised hosts. Inhalation of Nocardia leads to pulmonary disease. Microbiology laboratory processed the clinical samples from patients with respiratory infections. Smears were prepared from the samples and were stained and cultured. Five cases were positive for Nocardia. They were treated with the trimethoprim-sulfamethoxazole combination. The disease was cured in three patients, and two died due to other comorbid conditions leading to complications. Nocardiosis is encountered in parts of the world even where it is not endemic due to increased world travel. So physicians and laboratory staff should be aware of this and try to diagnose it. Early detection can lead to the prompt initiation of treatment and reduced mortality in these patients. Patients with disseminated or severe nocardiosis should be treated with combination therapy with two or more active agents.

1. Case Presentation

In the present study, five cases of pulmonary nocardiosis (PN), four males and one female, were encountered among patients attending Vallabhbhai Patel Chest Institute, a tertiary care respiratory diseases hospital in Delhi, India. They were admitted with complaints of breathlessness and increased cough with sputum production from a week to 3-month duration. They all had fever and weight loss. All were immunocompromised with four of them having the chronic obstructive pulmonary disease (COPD) with tuberculosis and one with COPD and diabetes mellitus. Sputum samples from four and bronchial alveolar lavage, bronchial aspirate, and sputum from one case showed Gram-positive filamentous branching rods with beaded appearance on Gram's staining and acid fast branching filamentous rods with beaded appearance on modified Ziehl-Neelsen staining suggestive of Nocardia. It was isolated on sheep blood agar from four cases. Patients were treated with trimethoprim-sulfamethoxazole (TMP-SMX) along with other antibiotics like amikacin and imipenem/meropenem. Three were discharged and advised to continue TMP-SMX for six months. Two of these were followed up and were completely free of symptoms, and their sputum was negative on smear and culture. Two of the patients died. Table 1 shows the details of the cases.

2. Discussion and Update

2.1. Introduction. Nocardia is widely distributed in dust, soil, water, and vegetable matter. Inhalation of the dust particles leads to pulmonary involvement commonly caused by N. asteroides complex. Direct inoculation of the organism can lead to infections of the skin and subcutaneous tissue. They can disseminate from pulmonary or cutaneous focus to virtually any organ.

2.2. Epidemiology and Risk Factors. Nocard first described Nocardia in 1888 [1] which was later described by Eppinger (1890), in a man with a pulmonary disease with “pseudotuberculosis” of lungs and pleura, caseous peribronchial lymph nodes, meningitis, and multiple abscesses in the brain [2]. Nocardia consists of more than 22 species of which N. asteroides complex, comprising of N. asteroides sensu stricto, N. farcinica, N. nova, and N. abscessus, is the most common. Agricultural occupation is a risk factor for pulmonary nocardiosis. Systemic immunosuppression, corticosteroid therapy, lymphoma, sarcoidosis, systemic lupus erythematosus, chronic alcoholism, diabetes mellitus, and human immunodeficiency virus (HIV) infection are other predisposing factors. Lately, it has been observed that COPD is also a risk factor for Nocardia infection [3].
### Table 1: Details of patients with pulmonary nocardiosis.

| Age  | Case 1 | Case 2 | Case 3 | Case 4 | Case 5 |
|------|--------|--------|--------|--------|--------|
| 76   | COPD with pulmonary T.B. | COPD with pulmonary T.B. | COPD with DM | Treated pulmonary T.B. | Treated pulmonary T.B. |
| 70   | Yes    | Yes    | Yes    | No     | Yes    |
| 70   | No     | No     | No     | No     | No     |
| 57   | Yes    | Yes    | Yes    | Yes    | No     |
| 42   | Yes    | No     | No     | No     | No     |

**Chief complaints**
- Breathlessness and increased cough with sputum for 4-5 days and loss of weight and appetite.
- Breathlessness and cough with sputum for 20 years acutely increased for two weeks and fever for 1 week.
- Breathlessness and cough with sputum for 15 days.
- Breathlessness and cough with sputum for 15 days.
- Breathlessness and cough with sputum for three months, intermittent fever for three months, and loss of weight.

**X-ray**
- Bilateral pneumonia.
- Bilateral pneumonia.
- —
- Right lower zone opacity.

**Clinical samples**
- Sputum.
- Sputum.
- Sputum.
- Sputum.

**SMEAR Grams**
- Gram positive branching filamentous rods with beads.
- Gram positive branching filamentous rods with beads.
- Gram positive branching filamentous rods with beads.
- Gram positive branching filamentous rods with beads.
- Gram positive branching filamentous rods with beads.

**Modified acid fast staining**
- Acid fast branching filamentous rods with beads.
- Acid fast branching filamentous rods with beads.
- Acid fast branching filamentous rods with beads.
- Acid fast branching filamentous rods with beads.
- Acid fast branching filamentous rods with beads.

**Culture on sheep blood agar**
- Positive after 48 hrs of incubation.
- Positive after 48 hrs of incubation.
- Culture-negative after seven days of incubation.
- Positive after three days of incubation.
- Positive after 48 hrs of incubation.

**Treatment**
- Inj Amikacin 4 days.
- Inj Amikacin 2 wks.
- Inj Amikacin 5 days.
- Inj Amikacin 2 weeks.
- Inj Amikacin 2 weeks.

**Outcome**
- Patient expired after six days of admission.
- Patient expired after six days of admission.
- Sputum negative after one week.
- Sputum was negative after one week of treatment.
- Smear-negative after seven days and after two weeks follow-up.

**Follow-up**
- —
- The patient was lost to follow-up.
- —
- —

COPD: chronic obstructive pulmonary disease.
ATT: antituberculous treatment.
DM: diabetes mellitus.
TMP-SMX: trimethoprim-sulfamethoxazole.
TB.: tuberculosis.
2.3. Clinical Presentation. Pulmonary nocardiosis can present as acute, subacute, or chronic supplicative infection with a tendency to remit or exacerbate. PN is usually suppurrative but granulomatous, or mixed variety may occur. Clinical manifestation includes pneumonia, endobronchial inflammatory masses, lung abscess, and cavitary disease with contiguous extension leading to effusion and empyema.

2.4. Radiological Findings. Irregular nodules, reticulonodular or diffuse pneumatic infiltrates, and pleural effusions are seen in X-ray. The progressive fibrotic disease may develop following inadequate therapy, and the diagnosis is often difficult. It can be fatal in patients with advanced HIV infection and often presents as alveolar infiltrates rather than cavitary lesion. In this situation, the X-ray findings are nonspecific and hence should be considered as a differential diagnosis of indolent pulmonary disease along with Mycobacteria, Actinomyces, and Eumycetes (Cryptococcus neoformans and Aspergillus species).

2.5. Laboratory Diagnosis. Demonstration of *Nocardia* in clinical sample clinches the diagnosis. Direct demonstration of *Nocardia* from sputum, bronchoalveolar lavage, bronchial aspirate, or endotracheal aspirate should be attempted. Gram's stain smear shows Gram-positive, beaded, fine, right-angled branching filaments (<1μm diameter) which may fragment to form rods and coccoid forms of varying sizes. Most isolates of *Nocardia* are acid fast by modified Kinyoun technique that differentiates it from Actinomyces which is not acid fast. Silver methenamine stain is equally useful and reliable as modified Ziehl-Neelsen staining [4]. *Nocardia* spp. grow on media used for culture of bacteria, fungi, and Mycobacteria. Typical colonies appear after three to five days. *Nocardia* spp. appear as either buff or pigmented waxy cerebiform colonies or have a dry, chalky-white appearance with the production of aerial hyphae.

Some commercial identification systems like API 20C (Biomerieux) allow for rapid identification of *Nocardia* spp., but have the limitation of the traditional phenotypic method [5].

Molecular identification of *Nocardia* is not only quick and accurate but also helps in the recognition of new species. Various methods like ribotyping, polymerase chain reaction, restriction fragment length polymorphism analysis, and DNA sequencing are available [6].

DNA sequencing is currently the best tool for species identification of *Nocardia*. Sequencing of first 500–606 base pairs of the 5′ end of 16S rRNA gene is the recommended method [6]. All these methods have their limitations and should be used with caution.

Currently, there are no serological tests available for diagnosis of active nocardiosis due to the cross-reactivity among different *Nocardia* species, Mycobacterium tuberculosis, *Mycobacterium leprae*, and other Actinomyces [7].

2.6. Management. Trimethoprim-sulfamethoxazole (TMP-SMX) is the mainstay of treatment and has improved the outcomes. In adults, with normal renal function and localized disease, the recommended daily dose of TMP-SMX is 5 to 10 mg/kg TMP and 25 to 50 mg/kg SMX in two to four divided doses, depending on the extent of disease. Higher initial doses (15 mg/kg TMP and 75 mg/kg SMX), given intravenously or orally, are frequently used in patients with cerebral abscesses; severe, extensive, or disseminated infection; or AIDS. Sulfonamides are the treatment of choice for disease due to *N. brasiliensis*. However, mortality with monotherapy is as high as 50% [8] especially in severely ill patients and those with cerebral involvement or disseminated nocardiosis and immune-suppression. Empirical combination therapy with amikacin and imipenem (or meropenem) or a three-drug regimen comprising of Sulphonamides, amikacin, and either a Carbapenem or third generation Cephalosporin can be used in such high-risk patients.

3. Conclusion

Isolation of nocardiae from sputum or blood occasionally represents colonization, transient infection, or contamination. In cases of respiratory tract colonization, Gram-stained specimens are usually negative, and cultures are only intermittently positive. Until a better tool to determine the virulence of *Nocardia* is available, the positive culture often reflects disease in immune-suppressed patients, such as patients on corticosteroid therapy, patients who undergo organ transplantation, patients with chronic lung disease, and HIV-positive patients. Therefore, PN must be suspected in patients with these risk factors and positive imaging findings. Early detection of the organism can lead to the prompt initiation of treatment and reduced mortality in these patients. Initial combination therapy with two or more active agents is recommended for patients with disseminated or severe nocardiosis.

Additional Points

**Learning Objectives.** (i) To recognize the importance of *Nocardia* in causing lung infections. (ii) To diagnose *Nocardia* in the laboratory. (iii) To treat infections caused by *Nocardia*.

**Pre-Test.** (1) How to diagnose Pulmonary Nocardiosis? (2) How can it be treated effectively?

**Post-Test.** (1) How to Diagnose Pulmonary Nocardiosis? Direct demonstration of *Nocardia* from clinical samples stained with Gram's stain and the modified acid fast stain will help in the diagnosis of Nocardiosis. *Nocardia* appears as Gram-positive filamentous branching rods with beaded appearance on Gram's staining and acid fast branching filamentous rods with beaded appearance on modified Ziehl-Neelsen staining. The diagnosis can further be confirmed by culturing the organism in solid media.

(2) How Can It Be Treated Effectively? Trimethoprim-sulfamethoxazole (TMP-SMX) is the mainstay of treatment. However, monotherapy may lead to treatment failures. Hence, empirical combination therapy with amikacin and
imipenem (or meropenem) or a three-drug regimen comprising Sulphonamides, amikacin, and either a Carbapenem or third generation Cephalosporin can be used in high-risk patients.

Disclosure

Work was carried out at Department of Microbiology, Vallabhbhai Patel Chest Institute, Delhi University, Delhi, India.

Competing Interests

The authors declare that there are no competing interests associated with this work.

Authors’ Contributions

Jayanthi Gunasekaran processed the samples and compiled the data. Malini Shariff supervised the lab work, interpreted the results, reviewed the subject, and wrote the paper.

Acknowledgments

The study was supported by Vallabhbhai Patel Chest Institute through their annual governmental funding.

References

[1] M. E. Nocard, "Note sur la maladie des boeufs de la guadeloupe connue sous le nom de farcin," Annales de l’Institut Pasteur, vol. 2, pp. 293–302, 1888.
[2] H. Eppinger, "Ueber eine neue pathogenic Cladothrix und eine durch sic hervorgerufene Pseudotuberculosis," Wiener Klinische Wochenschrift, vol. 3, article 321, 1890.
[3] C. W. Emmons, C. H. Binford, J. P. Utz, and K. J. Kwon-Chung, Medical Mycology, Lea & Febiger, Philadelphia, Pa, USA, 3rd edition, 1977.
[4] L. Garcia-Bellmunt, O. Sibila, I. Solanes, F. Sanchez-Reus, and V. Plaza, "Pulmonary nocardiosis in patients with COPD: characteristics and Prognostic Factors," Archivos de Bronconeumologia, vol. 48, no. 8, pp. 280–285, 2012.
[5] S. Mathur, R. Sood, M. Aron, V. K. Iyer, and K. Verma, "Cyto logic diagnosis of pulmonary nocardiosis: a report of 3 cases," Acta Cytologica, vol. 49, no. 5, pp. 567–570, 2005.
[6] B. A. Brown-Elliott, J. M. Brown, P. S. Convile, and R. J. Wallace Jr., "Clinical and laboratory features of the Nocardia spp. based on current molecular taxonomy," Clinical Microbiology Reviews, vol. 19, no. 2, pp. 259–282, 2006.
[7] M. M. Mcneil and J. M. Brown, "The medically important aerobic actinomycetes: epidemiology and microbiology," Clinical Microbiology Reviews, vol. 7, no. 3, pp. 357–417, 1994.
[8] R. J. Wallace Jr., E. J. Septimus, T. W. Williams Jr. et al., "Use of trimethoprim-sulfamethoxazole for treatment of infections due to Nocardia," Reviews of Infectious Diseases, vol. 4, no. 2, pp. 315–325, 1982.